Aug 6 |
Organon & Co. 2024 Q2 - Results - Earnings Call Presentation
|
Aug 6 |
Earnings summary: Organon & Co reports mixed Q2 results; narrows FY24 revenue outlook
|
Aug 6 |
Organon & Co in charts: Biosimilars revenue jumps 22% Y/Y in Q2, down sequentially
|
Aug 6 |
Organon Non-GAAP EPS of $1.12 beats by $0.04, revenue of $1.61B misses by $10M
|
Aug 6 |
Organon Reports Results for the Second Quarter Ended June 30, 2024
|
Aug 5 |
Organon Q2 Earnings Preview: Positive growth expected
|
Jul 30 |
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
|
Jul 30 |
Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
|
Jul 25 |
Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company
|
Jul 24 |
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
|